EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Erythematotelangiectatic Rosacea

Jian Li, Jinyu Wei, Mingwang Zhang, Minmin Kong, Lijuan Xie, Mei Wan, Zhifei Pan, Jing Tian, Zuzhen Ou, Shuguang Chen, Aiai Xia, Li Tang und 3 weitere

JAMA Dermatology · 2025

DOI: 10.1001/jamadermatol.2025.3796 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Jian Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Rosacea, Vagus Nerve Stimulation, Transcutaneous Electric Nerve Stimulation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Treatment of facial flushing and erythema for patients with erythematotelangiectatic rosacea (ETR) is challenging. Transcutaneous auricular vagus nerve stimulation (taVNS) therapy may be beneficial for treating ETR; however, it has not been rigorously evaluated in a randomized clinical trial.

Objective

To evaluate the efficacy of taVNS for ETR compared with sham stimulation (SS). Design, Setting, and Participants Enrollment for this single-center, randomized, double-blind, sham-controlled device clinical trial was initiated in February 2024 and ended in August 2024. The follow-up period ended in February 2025, and data were analyzed in March 2025. Patients with ETR that was accompanied by a Clinician’s Erythema Assessment (CEA) score of at least 2 were selected from the Department of Dermatology of Southwest Hospital in China.

Interventions

Patients were allocated to the taVNS group (stimulation pulses at a frequency of 30 Hz and a pulse width of 200 μs for 30 minutes per day) or the SS group at a 1:1 ratio. Both groups received 3 weeks of treatment and 24 weeks of follow-up. Main Outcomes and Measures The primary outcome was CEA score after 3 weeks of treatment. The secondary outcomes included improvements in erythema and facial flushing, sleep disorders, migraine, anxiety, fatigue, and depression, as measured via clinical tools.

Results

Seventy-two participants (67 female individuals [93.1%]; median [IQR] age: 29.5 [24.0-36.0] years) with ETR were randomized into either the taVNS (36 [50.0%]) or SS groups (36 [50.0%]). At 3 weeks, the mean (SD) CEA score was lower in the taVNS group than the SS group (1.56 [0.84] vs 2.47 [0.81]; mean difference, −0.92; 95% CI, −1.3 to −0.53; P < .001). Moreover, taVNS also reduced the severity of anxiety (mean difference, −5.42; 95% CI, −8.11 to −2.73; P < .001) and depression (mean difference, −6.22; 95% CI, −9.69 to −2.75; P < .001). This relief persisted until the follow-up period. The effects on sleep disorders, migraine, and fatigue were consistent with the previously described indicators. Adverse events were not common for taVNS (2 of 36 [5.6%]) and SS (3 of 36 [8.3%]). Conclusions and Relevance This randomized clinical trial demonstrated that treating ETR with taVNS concurrently ameliorated cutaneous symptoms and systemic comorbidities, and the results suggest that taVNS is a novel therapeutic option for ETR management. Trial Registration Chinese Clinical Trial Register Identifier: ChiCTR2400080637

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosaceaVagus Nerve StimulationTranscutaneous Electric Nerve StimulationHumansFemaleMaleDouble-Blind MethodTreatment OutcomeAdultMiddle AgedFollow-Up StudiesSeverity of Illness IndexErythema

Autor:innen und Institutionen

  • Department of Dermatology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
  • Department of Dermatology, The 920th Hospital of Joint Logistics Support Force of PLA, Kunming, China.
  • Department of Rehabilitation, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.

Zitieren

APA

Li, J., Wei, J., Zhang, M., Kong, M., Xie, L., Wan, M., Pan, Z., Tian, J., Ou, Z., Chen, S., Xia, A., Tang, L., Song, Z., Hou, J., & Hao, F. (2025). Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Erythematotelangiectatic Rosacea. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.3796

Vancouver

Li J, Wei J, Zhang M, Kong M, Xie L, Wan M, et al. Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Erythematotelangiectatic Rosacea. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2025.3796

BibTeX
@article{Li2025,
  author = {Li, Jian and Wei, Jinyu and Zhang, Mingwang and Kong, Minmin and Xie, Lijuan and Wan, Mei and Pan, Zhifei and Tian, Jing and Ou, Zuzhen and Chen, Shuguang and Xia, Aiai and Tang, Li and Song, Zhiqiang and Hou, Jingming and Hao, Fei},
  title = {Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Erythematotelangiectatic Rosacea},
  journal = {JAMA Dermatology},
  year = {2025},
  doi = {10.1001/jamadermatol.2025.3796}
}
Kostenlos starten →